These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 33408782)

  • 1. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 2. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
    Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
    Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
    Yang X; Wang J; Li H; Sun Y; Tong X
    Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
    Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
    J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
    He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
    Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer.
    Liu JQ; Feng YH; Zeng S; Zhong MZ
    Life Sci; 2020 Jan; 241():117134. PubMed ID: 31811854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
    Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
    Atwani R; Nagare RP; Rogers A; Prasad M; Lazar V; Sandusky G; Tong Y; Pin F; Condello S
    J Exp Clin Cancer Res; 2024 Jun; 43(1):156. PubMed ID: 38822429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells.
    Kim DK; Ham MH; Lee SY; Shin MJ; Kim YE; Song P; Suh DS; Kim JH
    BMB Rep; 2020 Dec; 53(12):622-627. PubMed ID: 32843129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.
    van Vlerken LE; Kiefer CM; Morehouse C; Li Y; Groves C; Wilson SD; Yao Y; Hollingsworth RE; Hurt EM
    Stem Cells Transl Med; 2013 Jan; 2(1):43-52. PubMed ID: 23283488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Yang T; Cheng J; You J; Yan B; Liu H; Li F
    Oncol Rep; 2018 Sep; 40(3):1574-1582. PubMed ID: 29956807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 20. LncRNA PART1 promotes cell proliferation and inhibits apoptosis of oral squamous cell carcinoma by blocking EZH2 degradation.
    Yu Q; Du Y; Wang S; Zheng X
    J Biochem; 2021 Sep; 169(6):721-730. PubMed ID: 33725092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.